Answers are grounded in this paper and cite their sources.
Chronic liver disease, particularly cirrhosis, produces a fragile, rebalanced hemostatic state. Patients may develop bleeding or thrombosis. The international normalized ratio and platelet count incompletely reflect concurrent procoagulant and anticoagulant changes and poorly predict procedural bleeding. Viscoelastic testing and thrombin-generation assays assess hemostasis more broadly. Randomized trials support viscoelastic testing-guided reductions in blood product use, but these trials do not establish prediction of later bleeding or thrombosis. Machine-learning models address gastrointestinal bleeding outcomes, variceal hemorrhage, portal vein thrombosis (PVT), and transfusion requirements using clinical records, imaging, or elastography. Most cirrhosis models address one outcome, omit direct hemostatic measurements, and have limited external validation. Within the English-language eligibility criteria and focused queries of a PubMed update on July 29, 2026, no adult model jointly estimating future bleeding and PVT in cirrhosis was identified. This structured narrative minireview evaluates the evidence for both outcomes and specifies research requirements for paired-risk models and a possible digital twin of the coagulation-portal axis. Treatment-specific predictions would require additional causal validation.
No takes yet. Share an insight, caveat, or question.
Ahmed Salman (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: